IV Saline for POTS and Long COVID
Trial Summary
Will I have to stop taking my current medications?
The trial may require you to stop taking certain medications if they could interfere with the test results, but it doesn't specify which ones. It's best to discuss your current medications with the trial team to see if any changes are needed.
Is IV saline generally safe for humans?
How does the IV saline treatment for POTS and Long COVID differ from other treatments?
IV saline treatment is unique because it involves administering a large volume (999 mL) of normal saline directly into the bloodstream, which can help improve blood volume and circulation. This approach is different from oral medications or lifestyle changes typically used for POTS and Long COVID, as it provides immediate hydration and electrolyte balance.678910
What is the purpose of this trial?
Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).
Research Team
Satish R Raj, MD MSCI
Principal Investigator
University of Calgary
Eligibility Criteria
This trial is for adults aged 18-60 with Long COVID or Postural Orthostatic Tachycardia Syndrome (POTS) who experience 'brain fog' or cognitive issues. Healthy individuals without POTS or brain fog can also participate. People must have had a positive SARS-CoV-2 test and symptoms persisting over 12 weeks.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 999 mL or 50 mL of normal saline intravenously, followed by cognitive and physiological testing
Follow-up
Participants complete a series of validated questionnaires to assess psychiatric symptoms
Treatment Details
Interventions
- IV normal saline (50 mL infusion)
- IV normal saline (999 mL infusion)
IV normal saline (999 mL infusion) is already approved in United States, European Union, Canada for the following indications:
- Dehydration
- Hypovolemia
- Shock
- Metabolic acidosis
- Hyponatremia
- Hypernatremia
- Fluid replacement
- Electrolyte disturbances
- Dehydration
- Hypovolemia
- Shock
- Metabolic acidosis
- Hyponatremia
- Hypernatremia
- Fluid replacement
- Electrolyte disturbances
- Dehydration
- Hypovolemia
- Shock
- Metabolic acidosis
- Hyponatremia
- Hypernatremia
- Fluid replacement
- Electrolyte disturbances
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor